Open access
Aug 2026
Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study
Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...
Thomas Pierret, J. Auliac, C. Ricordel et al.
· Current Oncology · 0 citations